Most diabetic type2 patients develop the cardiovascular complications. This development associate with increase of ADMA levels [competitive inhibitor of nitric oxide (NO)]. This suggest that asymmetric dimethylearginine plays a crucial role in the development of cardiovascular complications and it involves as a marker of cardiovascular risk. We determined serum ADMA levels of three individual groups: normal subjects (n=20), diabetic type2 patients (n=30), diabetic type2 with cardiovascular disease patients (n=30) by ELISA. Using this assay, we found that ADMA levels of diabetic type2 and diabetic type2 with cardiovascular disease patients were high compared with normal subjects. And Mean ±SD values were 0.4±0.18 µmol/l for normal subjects and 1.05±0.28 µmol/l for diabetic type2 patients and 1.90±0.49 µmol/l for diabetic type2 with cardiovascular disease patients . Our study revealed that ADMA plays a corporation role in developing the cardiovascular complications in diabetic type2 patients.